Kim TW - Search Results

1

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Eng C, et al. Among authors: kim tw. Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Lancet Oncol. 2019. PMID: 31003911 Clinical Trial.

2

Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.

Chang HM, Kim TW, Ryu BY, Choi SJ, Park YH, Lee JS, Kim WK, Kang YK. Chang HM, et al. Among authors: kim tw, kim wk. Jpn J Clin Oncol. 2005 May;35(5):251-5. doi: 10.1093/jjco/hyi077. Epub 2005 May 10. Jpn J Clin Oncol. 2005. PMID: 15886269 Clinical Trial.

3

Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group. Kim TW, et al. Among authors: kim sr, kim hk. Acta Oncol. 2005;44(3):230-5. doi: 10.1080/02841860510029590. Acta Oncol. 2005. PMID: 16076694 Clinical Trial.

4

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.

Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Lee SS, et al. Among authors: kim tw, kim wk. Jpn J Clin Oncol. 2007 Jan;37(1):30-7. doi: 10.1093/jjco/hyl134. Jpn J Clin Oncol. 2007. PMID: 17272321

5

A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, Kim MK, Sym SJ, Lee JS, Kang YK. Koo DH, et al. Among authors: kim tw, kim mk. J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S98-S103. doi: 10.3346/jkms.2007.22.S.S98. J Korean Med Sci. 2007. PMID: 17923763 Free PMC article. Clinical Trial.

6

Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.

Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK. Jo JC, et al. Among authors: kim tw. Jpn J Clin Oncol. 2007 Dec;37(12):936-41. doi: 10.1093/jjco/hym123. Jpn J Clin Oncol. 2007. PMID: 18211985

7

Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK. Sym SJ, et al. Among authors: kim tw. Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2. Am J Clin Oncol. 2008. PMID: 18391599

8

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Kang BW, et al. Among authors: kim tw, kim jc, kim jh. Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22. Med Oncol. 2009. PMID: 18498064

9

lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.

Kim YS, Kim JH, Yoon SM, Choi EK, Ahn SD, Lee SW, Kim JC, Yu CS, Kim HC, Kim TW, Chang HM. Kim YS, et al. Among authors: kim tw, kim jc, kim hc, kim jh. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):796-802. doi: 10.1016/j.ijrobp.2008.08.065. Epub 2009 Mar 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 19289261

10

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: kim tw, kim ty, kim mk. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,522 results

Search Page